Semaglutide vs tirzepatide: how they actually compare

What this guide covers

Two different molecules, two different receptor targets, and one head-to-head trial. What the SURPASS-2, STEP-1, and SURMOUNT-1 data show on weight, blood sugar, side effects, dosing, and cost, in plain language. This is patient education, not a substitute for the prescriber who knows your case. Generic names sit next to brand names throughout: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound).

Key points

• The short answer. Semaglutide (the molecule in Ozempic and Wegovy) and tirzepatide (the molecule in Mounjaro and Zepbound) are different drugs. Semaglutide acts on one receptor, GLP-1. Tirzepatide acts on two, GIP and GLP-1. In the one trial that compared them directly for type 2 diabetes (SURPASS-2, Frias 2021), tirzepatide produced more weight loss and a larger drop in HbA1c than semaglutide 1 mg. That does not automatically make it the right choice for any one person, because cost, access, side-effect tolerance, and what your prescriber is comfortable with all matter. Both are genuinely effective.
• Different molecules, different receptors. This is the part most comparisons skip. Semaglutide is a single-agonist: it mimics GLP-1, a gut hormone that slows gastric emptying, blunts appetite, and improves insulin response. Tirzepatide is a dual agonist: it does the GLP-1 job and also activates the GIP receptor, a second incretin pathway. The FDA prescribing information for each drug describes these mechanisms. The working theory in the trial literature is that hitting both incretin receptors is why tirzepatide tends to outperform on weight, but the GIP contribution is still an active research question, not settled science.
• Weight loss, head to head. In STEP-1 (Wilding 2021), semaglutide 2.4 mg (the Wegovy dose) produced an average 14.9% body-weight reduction at 68 weeks. In SURMOUNT-1 (Jastreboff 2022), tirzepatide reached an average of roughly 15% to 20.9% at 72 weeks depending on dose (5 mg up to 15 mg). The cleanest comparison is SURPASS-2, which put them side by side in type 2 diabetes: tirzepatide beat semaglutide 1 mg on weight at every dose. The honest caveat: SURPASS-2 used semaglutide 1 mg, the diabetes dose, not the 2.4 mg obesity dose, so it is not a perfectly matched fight. A direct trial at the higher obesity doses (SURMOUNT-5) has since reported tirzepatide ahead, but read each by name before drawing conclusions.
• Blood sugar. For type 2 diabetes, SURPASS-2 measured HbA1c head to head: all three tirzepatide doses lowered HbA1c more than semaglutide 1 mg, with the gap widening at higher tirzepatide doses. Both drugs are strong glucose-lowerers and both carry a low risk of hypoglycemia on their own. That risk rises when either is combined with insulin or a sulfonylurea, which is the situation where a dose of one of those companion drugs often needs to come down. That is a prescriber decision, not a self-adjustment.
• Side effects compared. The side-effect profiles look similar because they share the GLP-1 mechanism: nausea, diarrhea, constipation, and vomiting top both labels, heaviest right after a dose increase. Across the trials, gastrointestinal events were common on both and led a single-digit percentage of people to stop. There is no strong evidence that one is reliably gentler than the other for everyone, individual tolerance varies more than the drug-to-drug difference. If you are dealing with nausea or constipation, the management playbook is the same for both molecules.

Frequently asked questions